Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;304(5):1153-1160.
doi: 10.1007/s00404-021-06178-5. Epub 2021 Aug 14.

Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update

Xiaodong Li #  1 , Abdullah Shopit #  2 , Jingmin Wang  3
Affiliations
Review

Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update

Xiaodong Li et al. Arch Gynecol Obstet. 2021 Nov.

Abstract

Background: Autoimmune diseases as antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) could cause many maternal complications. The most common maternal complications of autoimmune diseases are lupus flare, hypertension, nephritis, preeclampsia (PE), eclampsia, and poor pregnancy outcomes which including preterm delivery and pregnancy loss. Only the lupus anticoagulant in the greatest prospective multicenter study has been associated with adverse pregnancy outcomes of the APS.

Purpose: This review aims to provide a comprehensive update for predictors in pregnant women with APS/SLE.

Methods: These data have been collected from clinical and pathological studies, systematic reviews, and meta-analysis.

Results: In recent years the SLE and APS demonstrated to have different and valuable clinical and biomarker predictors for the pregnancy outcome. Treatment of pregnant women with APS is low molecular weight heparin (LMWH) and aspirin; however, around 75% of this management is considered successful.

Conclusion: This review summarizes recent research that focuses on biochemical and clinical predictors of adverse pregnancy outcomes (APOs) of pregnant women with SLE and APS. Furthermore, we have collected more evidence that confirms the safety and efficacy of hydroxychloroquine (HCQ) preventing APOs.

Keywords: Adverse pregnancy outcomes; Antiphospholipid syndrome; Lupus anticoagulant; Predictors; Systemic lupus erythematosus.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Hamijoyo L, Martha JW, Hidayat S, Akbar MR, Tantono H, Sakasasmita S et al (2019) Risk factors for poor pregnancy outcome in systemic lupus erythematosus patients. Acta Med Indones 51(2):102–109 - PubMed
    1. Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA (2015) The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 11(5):301–312. https://doi.org/10.1038/nrrheum.2015.29 - DOI - PubMed - PMC
    1. Fredi M, Andreoli L, Aggogeri E, Bettiga E, Lazzaroni MG, Le Guern V et al (2018) Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: results from a multicenter study of 283 pregnancies. Front Immunol 9:864. https://doi.org/10.3389/fimmu.2018.00864 - DOI - PubMed - PMC
    1. Sciascia S, Radin M, Bazzan M, Roccatello D (2017) Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Intern Emerg Med 12(1):1–7. https://doi.org/10.1007/s11739-016-1596-2 - DOI - PubMed
    1. Radin M, Cecchi I, Schreiber K, Rubini E, Roccatello D, Cuadrado MJ et al (2020) Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their global antiphospholipid syndrome score. Semin Arthritis Rheum 50(3):553–556. https://doi.org/10.1016/j.semarthrit.2020.01.007 - DOI - PubMed

MeSH terms

LinkOut - more resources